Name | dorzagliatin |
---|---|
Synonyms |
(2S)-2-[4-(2-Chlorophenoxy)-2-oxo-2,5-dihydro-1H-pyrrol-1-yl]-N-{1-[(2R)-2,3-dihydroxypropyl]-1H-pyrazol-3-yl}-4-methylpentanamide
X59W6980E8 1H-Pyrrole-1-acetamide, 4-(2-chlorophenoxy)-N-[1-[(2R)-2,3-dihydroxypropyl]-1H-pyrazol-3-yl]-2,5-dihydro-α-(2-methylpropyl)-2-oxo-, (αS)- dorzagliatin 10511 |
Description | Dorzagliatin (HMS5552), a dual-acting glucokinase (GK) activator, improves glycaemic control and pancreatic β-cell function in type 2 diabetes[1]. |
---|---|
Related Catalog | |
Target |
Glucokinase[1] |
In Vivo | Dorzagliatin (low-dose 10 mg/kg, and high-dose 30 mg/kg; administered intragastrically; daily 8:00 AM for one month) exerts a glucose-lowering effect on the glucose levels in diabetic rats[2. Animal Model: Male Sprague-Dawley (SD) rats (aged approximately 6–8 weeks and weighing 200-230 g)[2 Dosage: Low-dose (10 mg/kg), and high-dose (30 mg/kg) Administration: Administered intragastrically (i.g.); daily (8:00 AM) for one month Result: Exerted a glucose-lowering effect on the glucose levels. |
References |
Density | 1.4±0.1 g/cm3 |
---|---|
Boiling Point | 761.7±60.0 °C at 760 mmHg |
Molecular Formula | C22H27ClN4O5 |
Molecular Weight | 462.927 |
Flash Point | 414.5±32.9 °C |
Exact Mass | 462.166992 |
LogP | 2.78 |
Vapour Pressure | 0.0±2.7 mmHg at 25°C |
Index of Refraction | 1.631 |